Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 10/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 6/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CDK9 | P50750 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509221 | 0.80 | DPP4 (0.44) | SCN9ADPP4DPP7DPP8 | |
| SCHEMBL2685859 | 0.76 | DPP4 (0.47) | DPP4DPP7HTR2ADPP8 | |
| SCHEMBL10054447 | 0.74 | CTSS (0.45) | SCN9AGPR119DPP4DPP7AAK1 | |
| SCHEMBL2364410 | 0.74 | CTSS (0.45) | SCN9AGPR119DPP4DPP7AAK1 | |
| SCHEMBL1509219 | 0.74 | CTSS (0.45) | SCN9AGPR119DPP4DPP7AAK1 | |
| SCHEMBL2351580 | 0.74 | DPP4 (0.40) | SCN9ADPP4DPP7AAK1DPP8 | |
| SCHEMBL5515657 | 0.74 | SCN9A (0.37) | SCN9AGPR119DPP4DPP7DPP8 | |
| SCHEMBL10054507 | 0.72 | SCN9A (0.45) | SCN9AGPR119DPP4DPP7AAK1 | |
| SCHEMBL12849500 | 0.72 | SCN9A (0.45) | SCN9AGPR119DPP4DPP7AAK1 | |
| SCHEMBL10054499 | 0.72 | SCN9A (0.45) | SCN9AGPR119DPP4DPP7AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168637-B2 | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes | MERCK SHARP & DOHME CORP. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100130504-A1 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130504-A1 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | SCN9A 2422/4885GPR119 125/4885DPP4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.